Sunovion Pharmaceuticals Overview
- Year Founded
-
1984
- Status
-
Acquired/Merged
- Employees
-
2,400
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.86B
Sunovion Pharmaceuticals General Information
Description
Provider of medical therapies designed to contribute to society through value creation based on research and development activities for the betterment of health care and fuller lives of people worldwide. The company's innovative therapies address serious psychiatric, neurological, and respiratory conditions, enabling people with serious medical conditions to lead fulfilling lives.
Contact Information
Website
www.sunovion.comCorporate Office
- 84 Waterford Drive
- Marlborough, MA 01752
- United States
Corporate Office
- 84 Waterford Drive
- Marlborough, MA 01752
- United States
Sunovion Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 20-Oct-2009 | $2.86B | Completed | Generating Revenue | ||
| 2. IPO | 20-Sep-1991 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 01-Jan-1985 | Completed | Startup |
Sunovion Pharmaceuticals Comparisons
Industry
Financing
Details
Sunovion Pharmaceuticals Competitors (18)
One of Sunovion Pharmaceuticals’s 18 competitors is Merck & Co., a Corporation company based in Rahway, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Mallinckrodt Pharmaceuticals | Formerly PE-Backed | Dublin, Ireland | ||||
| Mitsubishi Tanabe Pharma | Corporate Backed or Acquired | Osaka, Japan | ||||
| H. Lundbeck | Corporation | Copenhagen, Denmark |
Sunovion Pharmaceuticals Patents
Sunovion Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230170075-A1 | Management of psychiatric or mental conditions using digital or augmented reality with personalized exposure progression | Active | 01-Dec-2021 | ||
| US-12211607-B2 | Management of psychiatric or mental conditions using digital or augmented reality with personalized exposure progression | Active | 01-Dec-2021 | ||
| US-20230241024-A1 | Methods of treating metabolic disorders | Inactive | 23-Sep-2021 | ||
| JP-2024534580-A | Methods for treating metabolic disorders | Pending | 23-Sep-2021 | ||
| US-20230056779-A1 | Systems and methods for management of psychiatric or mental conditions using digital or augmented reality | Active | 20-Jul-2021 | G16H20/70 |
Sunovion Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sunovion Pharmaceuticals Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Domain Associates | Venture Capital | Minority | ||
| Glynn Capital | Venture Capital | Minority | ||
| Johnston Associates | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| SR One Capital Management | Venture Capital | Minority |
Sunovion Pharmaceuticals Investments & Acquisitions (7)
Sunovion Pharmaceuticals’s most recent deal was a Later Stage VC with Elixirgen Therapeutics for . The deal was made on 17-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Elixirgen Therapeutics | 17-Feb-2021 | Later Stage VC | Biotechnology | ||
| Cynapsus | 21-Oct-2016 | Merger/Acquisition | Pharmaceuticals | ||
| Sunovion Respiratory Development | 05-Sep-2012 | Merger/Acquisition | Drug Discovery | ||
| Sepracor Pharmaceuticals | 04-Jun-2008 | Merger/Acquisition | Pharmaceuticals | ||
| ACADIA Pharmaceuticals | 17-Jan-2006 | PIPE | Pharmaceuticals |
Sunovion Pharmaceuticals FAQs
-
When was Sunovion Pharmaceuticals founded?
Sunovion Pharmaceuticals was founded in 1984.
-
Where is Sunovion Pharmaceuticals headquartered?
Sunovion Pharmaceuticals is headquartered in Marlborough, MA.
-
What is the size of Sunovion Pharmaceuticals?
Sunovion Pharmaceuticals has 2,400 total employees.
-
What industry is Sunovion Pharmaceuticals in?
Sunovion Pharmaceuticals’s primary industry is Clinics/Outpatient Services.
-
Is Sunovion Pharmaceuticals a private or public company?
Sunovion Pharmaceuticals is a Private company.
-
What is the current valuation of Sunovion Pharmaceuticals?
The current valuation of Sunovion Pharmaceuticals is .
-
What is Sunovion Pharmaceuticals’s current revenue?
The current revenue for Sunovion Pharmaceuticals is .
-
Who are Sunovion Pharmaceuticals’s investors?
Domain Associates, Glynn Capital, Johnston Associates, New Enterprise Associates, and SR One Capital Management are 5 of 6 investors who have invested in Sunovion Pharmaceuticals.
-
Who are Sunovion Pharmaceuticals’s competitors?
Merck & Co., Novartis, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma, and H. Lundbeck are some of the 18 competitors of Sunovion Pharmaceuticals.
-
When was Sunovion Pharmaceuticals acquired?
Sunovion Pharmaceuticals was acquired on 20-Oct-2009.
-
Who acquired Sunovion Pharmaceuticals?
Sunovion Pharmaceuticals was acquired by Sumitomo Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
